 |
|
Natural compounds block autoimmune response in diabetes, arthritis
November 07, 2006UCI study identifies how treatment can limit impact of T cells in autoimmune diseases
Irvine, Calif. - Natural compounds derived from a sea anemone extract and a shrub plant have been found to block the autoimmune disease response in type-1 diabetes and rheumatoid arthritis, according to University of California, Irvine researchers.
The study shows both in human and animal tests how these compounds work to deter the effect of autoimmune T-cells, white blood cells that attack the body. The goal, according to UCI researchers, is to develop new treatments from these compounds that will target these destructive T-cells while allowing other white blood cells to fight disease and infection.
Study results appear Nov. 6-10 in the Early Online Edition of the Proceedings of the National Academy of Sciences.
The study, led by UC Irvine School of Medicine researchers George Chandy and Christine Beeton, identifies how these compounds work against a type of white blood cells called effector memory T lymphocytes, which play a major role in autoimmunity. Both compounds block an ion channel in these cells that prevents the cells from proliferating and producing chemicals called cytokines that attack the body during autoimmune disease states.
"Autoimmune diseases affect millions of Americans, and any new therapies that can aid them will have great significance," Chandy said. "What's promising about this study is that we identified a protein target on the T-cells that promote autoimmune activity and the compounds that can selectively block the target and shut down the destructive cells."
White blood cells patrol the body to fight against cancer and infections, but if some of these cells turn against the body they are meant to protect, they cause autoimmune diseases. Millions of people worldwide are afflicted with disabling autoimmune disorders. Two examples of this large class of diseases are type-1 diabetes, in which white blood cells attack the pancreas, and rheumatoid arthritis, in which the joints are attacked.
In their study, the UCI researchers used modified compounds derived from the rue plant (PAP-1) and a Cuban sea anemone extract (SL5), both of which block the ion channel in the destructive T-cells.
In one set of tests using blood samples from type-1 diabetes patients and joint fluid from people with rheumatoid arthritis, the researchers found that both compounds suppressed the function of the autoimmune T-cells without affecting other T-cells that fight infections.
In another set of tests using rats, the compound from the rue shrub plant delayed the onset and reduced the incidence of disease in diabetic rats, while the venom compound stopped the progression of the disease and improved the joint function of rats with experimental autoimmune arthritis. In these rat tests, the compounds were nontoxic.
The Chandy laboratory previously discovered that SL5 compound was effective in treating rats with an experimental model of multiple sclerosis, another devastating autoimmune disease. Preclinical safety studies on PAP-1 and SL5 are under way in collaboration with AIRMID, a biotech company in the San Francisco Bay Area.
"We began our work on these natural products many years ago when we came across a report that described the beneficial effect of a scorpion sting on a patient with multiple sclerosis," Beeton said. "This work also speaks to the importance of protecting our plant and animal biodiversity - you never know where a new medicine will come from."
Heike Wulff from University of California, Davis is a co-lead author, and other authors from UCI, UC Davis, Johns Hopkins University, Bachem Biosciences and the Benaroya Research Institute in Seattle are noted in the study text. The National Institutes of Health, American Diabetes Association, Juvenile Diabetes Research Foundation, National Multiple Sclerosis Society, Arthritis National Research Foundation and David Israelsky provided support for this study.
About type-1 diabetes and rheumatoid arthritis: The American Diabetes Association estimates that type-1 diabetes mellitus, also known as juvenile diabetes, affects one in every 400 or 600 children and adolescents in the U.S. It is characterized by a destruction of the cells that produce insulin in the pancreas. Without enough insulin, the body cannot correctly regulate levels of blood glucose, a major source of energy for the body. Type-1 diabetes can lead to serious complications such as heart disease, blindness, and nerve or kidney damage.
In rheumatoid arthritis, white blood cells induce inflammation in the joints, leading to muscle and joint aches, stiffness, and fatigue. According to the Arthritis Foundation, rheumatoid arthritis is one of the most serious and disabling types, affecting mostly women. An estimated 2.1 million people in the U.S. have rheumatoid arthritis. Some recent studies have suggested that the overall number of new cases of rheumatoid arthritis actually may be going down.
University of California - Irvine
Study results appear Nov. 6-10 in the Early Online Edition of the Proceedings of the National Academy of Sciences.
The study, led by UC Irvine School of Medicine researchers George Chandy and Christine Beeton, identifies how these compounds work against a type of white blood cells called effector memory T lymphocytes, which play a major role in autoimmunity. Both compounds block an ion channel in these cells that prevents the cells from proliferating and producing chemicals called cytokines that attack the body during autoimmune disease states.
"Autoimmune diseases affect millions of Americans, and any new therapies that can aid them will have great significance," Chandy said. "What's promising about this study is that we identified a protein target on the T-cells that promote autoimmune activity and the compounds that can selectively block the target and shut down the destructive cells."
White blood cells patrol the body to fight against cancer and infections, but if some of these cells turn against the body they are meant to protect, they cause autoimmune diseases. Millions of people worldwide are afflicted with disabling autoimmune disorders. Two examples of this large class of diseases are type-1 diabetes, in which white blood cells attack the pancreas, and rheumatoid arthritis, in which the joints are attacked.
In their study, the UCI researchers used modified compounds derived from the rue plant (PAP-1) and a Cuban sea anemone extract (SL5), both of which block the ion channel in the destructive T-cells.
In one set of tests using blood samples from type-1 diabetes patients and joint fluid from people with rheumatoid arthritis, the researchers found that both compounds suppressed the function of the autoimmune T-cells without affecting other T-cells that fight infections.
In another set of tests using rats, the compound from the rue shrub plant delayed the onset and reduced the incidence of disease in diabetic rats, while the venom compound stopped the progression of the disease and improved the joint function of rats with experimental autoimmune arthritis. In these rat tests, the compounds were nontoxic.
The Chandy laboratory previously discovered that SL5 compound was effective in treating rats with an experimental model of multiple sclerosis, another devastating autoimmune disease. Preclinical safety studies on PAP-1 and SL5 are under way in collaboration with AIRMID, a biotech company in the San Francisco Bay Area.
"We began our work on these natural products many years ago when we came across a report that described the beneficial effect of a scorpion sting on a patient with multiple sclerosis," Beeton said. "This work also speaks to the importance of protecting our plant and animal biodiversity - you never know where a new medicine will come from."
Heike Wulff from University of California, Davis is a co-lead author, and other authors from UCI, UC Davis, Johns Hopkins University, Bachem Biosciences and the Benaroya Research Institute in Seattle are noted in the study text. The National Institutes of Health, American Diabetes Association, Juvenile Diabetes Research Foundation, National Multiple Sclerosis Society, Arthritis National Research Foundation and David Israelsky provided support for this study.
About type-1 diabetes and rheumatoid arthritis: The American Diabetes Association estimates that type-1 diabetes mellitus, also known as juvenile diabetes, affects one in every 400 or 600 children and adolescents in the U.S. It is characterized by a destruction of the cells that produce insulin in the pancreas. Without enough insulin, the body cannot correctly regulate levels of blood glucose, a major source of energy for the body. Type-1 diabetes can lead to serious complications such as heart disease, blindness, and nerve or kidney damage.
In rheumatoid arthritis, white blood cells induce inflammation in the joints, leading to muscle and joint aches, stiffness, and fatigue. According to the Arthritis Foundation, rheumatoid arthritis is one of the most serious and disabling types, affecting mostly women. An estimated 2.1 million people in the U.S. have rheumatoid arthritis. Some recent studies have suggested that the overall number of new cases of rheumatoid arthritis actually may be going down.
University of California - Irvine
Autoimmune Response Current Events and Autoimmune Response News RSSNew link found between osteoporosis and coeliac disease
People with coeliac disease may develop osteoporosis because their immune system attacks their bone tissue, a new study has shown.
UM scientists pinpoint critical molecule to celiac disease, possibly other autoimmune disorders
It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes.
Device Protects Transplanted Pancreatic Cells from the Immune System
Scientists at Burnham Institute for Medical Research (Burnham) and the University of California San Diego (UC San Diego) School of Medicine have demonstrated in mice that transplanted pancreatic precursor cells are protected from the immune system when encapsulated in polytetrafluorethylene (PTFE).
MDC researchers prevent virus induced myocarditis
Life-threatening cardiac arrhythmia can be a consequence of myocarditis - an inflammation of the cardiac muscle that can be caused by the Coxsackievirus.
Don't be a stranger to yourself
One of the most important tasks of the immune system is to identify what is foreign and what is self. If this distinction fails, then the body's own structures will be attacked, the result of which could be an autoimmune disease such as diabetes mellitus type 1 or multiple sclerosis.
UCSF finds potential new antibody treatment for autoimmune diseases
Scientists at UCSF have discovered an abnormality in a patient's immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection.
New scientific knowledge on juvenile diabetes
Finnish scientists have reported a breakthrough in the attempts to understand the development of type 1 diabetes. They discovered disturbances in lipid and amino acid metabolism in children who later progressed to type 1 diabetes, also known as juvenile diabetes.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
Accumulated bits of a cell's own DNA can trigger autoimmune disease
A security system wired within every cell to detect the presence of rogue viral DNA can sometimes go awry, triggering an autoimmune response to single-stranded bits of the cell's own DNA, according to a report in the August 22nd issue of the journal Cell, a Cell Press publication.
Study Underway to Find an Alternative Cure for Crohn's Disease and Ulcerative Colitis
Two research studies evaluating dietary changes and complementary medicine for the treatment of inflammatory bowel diseases (IBD) have been launched at Rush University Medical Center.
More Autoimmune Response Current Events and Autoimmune Response News Articles
|
Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA.(Research): An article from: Environmental Health Perspectives by Jean C. Pfau (Author), Jami J. Sentissi (Author), Greg Weller (Author), Elizabeth A. Putnam (Author) This digital document is an article from Environmental Health Perspectives, published by Thomson Gale on January 1, 2005. The length of the article is 6015 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA.(Research) Author: Jean C. Pfau Publication: Environmental Health Perspectives (Magazine/Journal) Date: January 1, 2005 Publisher: Thomson Gale Volume: 113 Issue: 1 Page: 25(6) Distributed by Thomson... | |
 |
Immune Regulation and Immunotherapy in Autoimmune Disease by Jingwu Zhang (Editor) This volume will review the most recent advances in the understanding of cellular and molecular mechanisms for immune responses and immune regulation. Chapters in the first portion of this book will discuss the theoretical basis for current immunotherapies for autoimmune diseases. The second portion of the book will provide an updated review on the research behind the clinical trials/immunotherapies (e.g. T-cell vaccination, antibody therapy, etc.) in the areas of autoimmune diseases by the principal investigators of these studies. These chapters will discuss clinical and basic research as well as immunological data in the context of cellular and molecular mechanisms of the therapies. The book will finish with chapters by leaders in the field who will provide expert views on challenges... |
 |
Biologic and Gene Therapy of Autoimmune Disease (Current Directions in Autoimmunity) by C. Garrison Fathman (Editor) The clinical management of autoimmune diseases has proven to be extremely difficult. Current therapies focus on trying to alleviate symptoms, but fail to correct the fundamental immune defects that lead to pathology. To achieve this goal, it is necessary to understand much of the biology of antigen presentation, lymphocyte activation and the effects of cytokines. The articles in this book provide an up-to-date review of current innovative therapies using both biologic and gene therapy for the treatment of selected autoimmune diseases. Therapeutical approaches discussed include oral tolerance, the use of anti-CD4 monoclonal antibodies, IL-10 and anti-TNFa antibodies, DNA vaccination, and gene therapy applied to organ-specific autoimmune disease. Although some of these techniques are still... |
 |
T Cell Subsets in Infectious and Autoimmune Diseases - Symposium No. 195 by CIBA Foundation Symposium (Author) Mature T cells are classified on the basis of their surface marker proteins, such as CD4 and CD8. CD4+ and CD8+ cells recognize antigens associated with major histocompatibility complex class II and class I molecules, respectively, and they can both be further classified into subgroups. The division of CD4+ T cells into T helper 1 (Th1) and Th2 cells is based on the secretion of distinct patterns of cytokines, and the resulting polarized Th1 and Th2 responses play different roles in protection and the promotion of different immunopathological reactions. In contrast, CD8+ T cells are strongly cytotoxic; however, they can also secrete Th1-like or Th2-like cytokine profiles. This suggests that there is an increasingly complex network of cytokine regulatory patterns which are produced in... |
 |
Cytokines and Chemokines in Autoimmune Disease (Advances in Experimental Medicine and Biology) by Pere Santamaria (Editor), Peter Hackett (Editor) Univ. of Calgary, Canada. Text provides current knowledge on the role of cytokines and chemokines in autoimmunity by focusing on prevalent organ-specific or systemic autoimmune disorders that affect humans. Discusses such topics as receptors and their genes, immunoregulation, and tissue destruction. |
|
Autoimmunoregulation and Autoimmune Disease (Concepts in Immunopathology) by J. M. Cruse (Author), R. E. Lewis (Editor) | |
 |
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders by Elaine A. Moore (Author), Dr. Yash P. Agrawal (Foreword), Samantha Wilkinson (Foreword) Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies,... |
 |
Cytokines and Autoimmune Diseases by Vijay K. Kuchroo (Editor), Nora Sarvetnick (Editor), David A. Hafler (Editor), Lindsay B. Nicholson (Editor) Harvard Medical School, Boston, MA. Features state-of-the-art review of the role of cytokines in the induction and regulation of autoimmunity. Includes an examination of the role of cytokines in a variety of diseases and indication of the potential of cytokine modulation in the treatment of autoimmune diseases. DNLM: Autoimmune Diseases--immunology. |
 |
Interferon: The 50th Anniversary (Current Topics in Microbiology and Immunology) by Paula M. Pitha (Author), Paula M. Pitha (Editor) Over the last half of century interferon (IFN), originally discovered as an antiviral protein, has developed from an inhibitor of viral replication to a major force in the antiviral response. Initially studied only by few virologists, IFN was generally considered as a poorly defined protein of limited importance. The development of molecular techniques lead to the identification of a family of IFN genes and has shown an unexpected complexity of type I IFN genes and their expression. Presently, some aspects of the of the pathogen mediated induction of IFN gene expression are understood at molecular level, while others are still at the stage of description. Both Toll like receptors and cytoplasmic RNA helicases were shown to recognize viral nucleic acids and the basis of a distinct... |
 |
Epitope Recognition Since Landsteiner's Discovery by M. Eibl (Editor), W.R. Mayr (Editor), G.J. Thorbecke (Editor) Karl Landsteiner is best known for his discovery of the human blood goups. The revolutionary discoveries of this brilliant scientist in other fields have not received the recognition they deserve. His demonstration that poliomyelitis is transmissable showed the way of modern virology. His studies opening the field for epitope recognition, which he himself considered his main achievement, laid the foundation for research ongoing in our days. This book with its outstanding contributors is but a small tribute to this visionary scientist. |
| © 2009 BrightSurf.com |